Aytu bioscience, inc (AYTU)
CashFlow / Yearly
Jun'19Jun'18Jun'17Jun'16Jun'15Jun'14Aug'13Aug'12Aug'11
Net loss

-27,131

-10,187

-22,508

-28,180

-7,723

-5,578

-57

-59

-136

Deferred taxes

-

-

-

-

-23

-813

-

-

-

Adjustments to reconcile net loss to cash used in operating activities
Issuance of restricted stock

-

-

724

0

-

-

-

-

-

Depreciation, amortization and accretion

2,727

2,591

4,364

874

118

97

-

-

-

Impairment of intangible assets

0

1,856

-

-

-

-

-

-

-

Impairment of intangible assets

-

-

1,265

7,500

0

-

-

-

-

Stock-based compensation expense and restricted stock issuance

1,022

596

2,502

902

1,017

499

-

-

-

Amortization of debt issuance costs

-

-

-

182

0

-

-

-

-

Amortization of beneficial conversion feature

-

-

-

4,943

0

-

-

-

-

Noncash interest expense

-

-

-

221

0

-

-

-

-

(Loss) / gain from change in fair value of contingent consideration

-9,830

6,277

-

-12

0

-

-

-

-

Warrants issuance and amendments

0

183

-

-

-

-

-

-

-

Amortization of prepaid research and development - related party (Note 9)

-

-

335

121

121

35

-

-

-

Loss on investment

-

-

-61

-

0

-

-

-

-

Loss on investment

-

-

-

-971

-

-

-

-

-

Common stock issued to executives

-

-

-

0

-

-

-

-

-

Common stock issued to executives

-

-

-

0

-

-

-

-

-

Issuance of common stock to employee

11

0

509

-

-

-

2

0

60

Other gain

-

-

0

-

-

-

-

-

-

Warrants issuance and amendments

-

-

1

-

-

-

-

-

-

Derivative income

80

3,983

212

-

-

-

-

-

-

Issuance of warrants to initial investors

-

-

596

0

-

-

-

-

-

Gain on sale of asset

-

-

428

0

-

-

-

-

-

Warrant amendment

-

-

-

0

-

-

-

-

-

Depreciation expense

-

-

-

-

-

-

4

6

6

Contributed capital to fund expenses

-

-

-

-

-

-

6

7

4

Changes in operating assets and liabilities:
(Increase) in accounts receivable

1,162

50

355

5

157

-

-

-

-

(Increase) in inventory

101

26

-195

485

39

-

-

-

-

(Increase) in prepaid expenses and other

517

129

95

-155

-150

497

-0

-0

0

(Increase) in prepaid research and development - related party

-

-

-

-

-150

-465

-

-

-

(Increase) decrease in security deposits

-

-

-

-

-

-

-0

0

-

(Decrease) in accounts payable and other

134

-109

493

698

547

-

6

8

1

Increase in accrued liabilities

961

-596

-414

925

-

-

-

-

-

Increase in related party payable

-

-

-

-

-

421

-

-

-

Increase in accrued compensation

308

200

-861

1,004

196

-

-

-

-

Increase in interest payable

-

-

-

-

-607

561

-

-

-

Increase in interest payable

166

0

-

-

-

46

-

-

-

(Decrease) in deferred rent

-

-

-

-10

0

-

-

-

-

(Decrease) in deferred rent

-1

-6

-4

-511

-85

191

-

-

-

Net cash used in operating activities

-13,831

-15,940

-13,829

-

-

-

-37

-37

-64

Net cash used in operating activities

-

-

-

-10,657

-6,634

-5,501

-

-

-

Cash flows used in investing activities
Deposit

-2

2

0

-1

4

-

-

-

-

Purchases of fixed assets

59

74

111

252

0

9

0

0

0

Contingent consideration payment

505

7

0

-

-

-

-

-

-

Cash received from acquisition

-

-

613

0

-

-

-

-

-

Purchase of assets

-

-

6,000

2,000

-

-

-

-

-

Investment in Acerus

-

-

1,071

-

-

-

-

-

-

Sale of investment in Acerus cost

-

-

91

-

-

-

-

-

-

Sales of Primsol assets

-

-

-1,750

-

-

-

-

-

-

Investment in Acerus

-

-

-

2,012

-

-

-

-

-

Purchase payment for Natesto asset

-

-

-

-

1,000

-

-

-

-

Sale of investment in Acerus cost

-

-

-

0

-

-

-

-

-

Sales of Primsol assets

-

-

-

0

-

-

-

-

-

Purchase of assets

500

400

750

1,040

-

-

-

-

-

Cost related to Nuelle acquisition

-

-

16

0

-

-

-

-

-

Net cash used in investing activities

-1,061

-484

-3,534

-

-

-

0

0

0

Net cash used in investing activities

-

-

-

-5,303

-1,004

-9

-

-

-

Cash flows from financing activities
S-3 registered offering cost

-

-

0

-

-

-

-

-

-

Issuance of common stock to Lincoln Park

-

-

739

0

0

-

5

18

43

Issuance costs related to preferred, common stock and warrants

-

-

90

0

0

-

-

-

-

Over-allotment warrants purchased by placement agents

-

-

-

0

-

-

-

-

-

Luoxis option payout pursuant to the merger

-

-

-

-

27

-

-

-

-

Liabilities paid out pursuant to the merger

-

-

-

-

20

-

-

-

-

Issuance of preferred, common stock and warrants

15,180

11,839

0

-

0

-

-

-

-

Issuance costs related to preferred, common stock and warrants

1,479

1,402

0

-

-

-

-

-

-

Issuance of preferred, common stock and warrant

0

12,900

-

-

-

-

-

-

-

Issuance costs related to preferred, common stock and warrant

0

1,294

-

-

-

-

-

-

-

Issuance of preferred, common stock and warrants

-

-

0

-

-

-

-

-

-

Issuance costs related to preferred, common stock and warrants

-

-

0

-

-

-

-

-

-

Warrant exercises

375

677

0

-

-

-

-

-

-

Warrants issued to investors and underwriters (see Note 6)

-

-

0

-

-

-

-

-

-

Earn-out payment to Nuelle Shareholders

0

250

0

-

-

-

-

-

-

Purchase of asset included in contingent consideration

0

293

-

-

-

-

-

-

-

Warrants issued in connection with the equity financing to the placement agents

-

-

292

0

-

-

-

-

-

Warrants amended in connection with warrant tender offer

-

-

63

0

-

-

-

-

-

Net change in cash

-

-

-

-

-

-

1

-3

2

Cash paid during the period for Income taxes

-

-

-

-

-

-

0

0

0

Cash paid during the period for Interest

-

-

-

-

-

-

0

0

2

Ampio stock subscription

-

-

-

-

5,000

-

-

-

-

Preferred stock converted in common stock

-

-

-

-

4,600

-

-

-

-

S-3 registered offering cost

0

60

-

-

-

-

-

-

-

Issuance of note payable

5,000

0

-

-

-

-

-

-

-

Warrant tender offer

-

-

2,243

-

-

-

-

-

-

Warrant tender offer cost

-

-

-312

-

-

-

-

-

-

Registerd offering

-

-

-

7,520

-

-

-

-

-

Registered offering costs

-

-

-8,602

904

-

-

-

-

-

Warrant tender offer

-

-

-

0

-

-

-

-

-

Warrant tender offer cost

-

-

-

0

-

-

-

-

-

Warrant tender offer

-

-

-

0

-

-

-

-

-

Warrant tender offer cost

-

-

-

0

-

-

-

-

-

Proceeds from convertible promissory notes, net (Note 8)

-

-

-

5,175

0

4,600

-

-

-

Debt issuance costs (Note 8)

-

-

-

298

0

-

-

-

-

Costs related to the conversion of the convertible promissory notes to equity

-

-

-

29

0

-

-

-

-

Proceeds from convertible note from Ampio converted to stock

-

-

-

-

7,400

-

31

16

35

Ampio stock subscription payment

-

-

-

5,000

5,000

-

-

-

-

Registered offering

-

-

-

7,520

-

-

-

-

-

Registered offering

-

-

-8,602

904

-

-

-

-

-

Registered offering costs

-

-

-997

-

-

-

-

-

-

Over-allotment warrants purchased by placement agents

-

-

2

-

-

-

-

-

-

Fixed assets included in accounts payable

-

-

10

0

-

-

-

-

-

Warrants issued in connection with the equity financing to the placement agents

-

-

292

0

-

-

-

-

-

Warrants amended in connection with warrant tender offer

-

-

63

0

-

-

-

-

-

Common stock subscription

-

-

-

-

-

-

3

0

-

Payments on related party loans

-

-

-

-

-

-

0

1

12

Net cash provided by financing activities

19,075

22,659

10,187

-

-

-

39

33

67

Sale of stock subscription

-

-

-

200

-

-

-

-

-

Contribution from Ampio

-

-

-

-

-

637

-

-

-

Net cash provided by financing activities

-

-

-

16,662

12,352

5,237

-

-

-

Net change in cash, restricted cash and cash equivalents

4,181

6,234

-7,176

701

4,713

-274

-

-

-

Supplemental disclosures of cash and non-cash investing and financing transactions
Warrants issued to investors and underwriters (see Note 13)

1,888

4,117

-

-

-

-

-

-

-

Warrant exercise of derivative warrants

0

40

0

-

-

-

-

-

-

Contingent consideration included in accounts payable

42

8

0

-

-

-

-

-

-

Contingent consideration related to product acquisition (Note 4)

8,833

2,553

-

-

664

-

-

-

-

Issuance of preferred stock related to purchase of asset

519

0

-

-

-

-

-

-

-

Conversion of debt to equity

5,166

0

-

-

-

-

-

-

-

Purchase of asset included in contingent consideration

0

293

0

-

-

-

-

-

-

Contingent consideration

-

-

0

-

-

-

-

-

-

Issuance of common stock to Nuelle share holders

-

-

1,837

0

-

-

-

-

-

Fixed assets included in accounts payable

-

-

10

0

-

-

-

-

-

Warrant derivative liability related to the issuance of the convertible promissory notes (Note 8)

-

-

-

102

0

-

-

-

-

Primsol asset purchase included in Primsol payable, $1,250,000 less future accretion of $173,000

-

-

-

1,077

0

-

-

-

-

Conversion of convertible promissory notes and interest of $221,000 to common stock

-

-

-

5,396

0

-

-

-

-

Natesto asset purchase included in Natesto payable, $6,000,000 less future accretion of $620,325

-

-

-

5,379

-

-

-

-

-

Natesto asset purchase included in Natesto payable, $6,000,000 less future accretion of $620,325

-

-

-

5,379

0

-

-

-

-

Warrant derivative liability related to the issuance of the registered offering placement agent warrants (Note 8)

-

-

-

297

0

-

-

-

-

Reclassification of liability based warrants to equity presentation related to the convertible promissory notes

-

-

-

136

0

-

-

-

-

Beneficial conversion feature related to convertible promissory notes

-

-

-

4,943

0

-

-

-

-

Debt issuance costs related to notes that converted to equity

-

-

-

-218

0

-

-

-

-

Issuance of common stock in exchange for Vyrix acquired assets

-

-

-

-

-

6,803

-

-

-

Related party research and development liability included in prepaid research and development-related party

-

-

-

-

-

150

-

-

-

Common stock issued for services

-

-

-

-

-

-

-

-

60